Article (Scientific journals)
Evaluation of a new biocompatible poly(N-(morpholino ethyl methacrylate)-based copolymer for the delivery of ruthenium oligonucleotides, targeting HPV16 E6 oncogene
Reschner, Anca; Shim, Yong Ho; Dubois, Philippe et al.
2013In Journal of Biomedical Nanotechnology, 9, p. 1-9
Peer reviewed
 

Files


Full Text
proof.pdf
Publisher postprint (751.53 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
polyplex; nanomedicine; PDMAEMA
Abstract :
[en] This study investigates the use of a new biocompatible block copolymer poly(2-(dimethylamino)ethyl methacrylate-N-(morpholino)ethyl methacrylate (PDMAEMA-b-PMEMA) for the delivery of a particular antisense oligonucleotide targeting E6 gene from human papilloma virus. This antisense oligonucleotide was derivatized with a polyazaaromatic RuII complex which, under visible illumination, is able to produce an irreversible crosslink with the complementary targeted sequence. The purpose of this study is to determine whether by the use of a suitable transfection agent, it is possible to increase the efficiency of the antisense oligonucleotide targeting E6 gene, named Ru-P-4. In a recent study, we showed that Oligofectamine® transfected Ru-P-4 antisense oligonucleotide failed to inhibit efficiently the growth of cervical cancer cell line SiHa, contrarily to the Ru-P-6 antisense oligonucleotide, another sequence also targeting the E6 gene. The ability of PDMAEMA-b-PMEMA to form polyplexes with optimal physicochemical characteristics was investigated first. Then the ability of the PDMAEMA-b-PMEMA/Ru-P-4 antisense oligonucleotide polyplexes to transfect two keratinocyte cell lines (SiHa and HaCat) and the capacity of polyplexes to inhibit HPV16 + cervical cancer cell growth was evaluated. PDMAEMA-b-PMEMA base polyplexes at the optimal molar ratio of polymer nitrogen atoms to DNA phosphates (N/P), were able to deliver Ru-P-4 antisense oligonucleotide and to induce a higher growth inhibition in human cervical cancer SiHa cells, compared to other formulations based on Oligofectamine®.
Research center :
Centre Interfacultaire de Recherche du Médicament - CIRM
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Reschner, Anca ;  Université de Liège - ULiège > Immunologie et vaccinologie
Shim, Yong Ho
Dubois, Philippe
Delvenne, Philippe ;  Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques
Evrard, Brigitte  ;  Université de Liège - ULiège > Département de pharmacie > Pharmacie galénique
Marcelis, Lionel
Moucheron, Cécile
Kirsch-De Mesmaeker, Andrée
Defrancq, Eric
Raes, Martine
Piette, Jacques ;  Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Virologie - Immunologie
Collard, Laurence ;  Université de Liège - ULiège > Département de pharmacie > Pharmacie galénique
Piel, Géraldine ;  Université de Liège - ULiège > Département de pharmacie > Pharmacie galénique
More authors (3 more) Less
Language :
English
Title :
Evaluation of a new biocompatible poly(N-(morpholino ethyl methacrylate)-based copolymer for the delivery of ruthenium oligonucleotides, targeting HPV16 E6 oncogene
Publication date :
2013
Journal title :
Journal of Biomedical Nanotechnology
Volume :
9
Pages :
1-9
Peer reviewed :
Peer reviewed
Available on ORBi :
since 12 March 2013

Statistics


Number of views
162 (39 by ULiège)
Number of downloads
6 (5 by ULiège)

Scopus citations®
 
14
Scopus citations®
without self-citations
10
OpenCitations
 
12

Bibliography


Similar publications



Contact ORBi